Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
J Oncol. 2008;2008:907892. doi: 10.1155/2008/907892. Epub 2008 Sep 23.
Alimentary mucositis is a major dose-limiting toxicity associated with anticancer treatment. It is responsible for reducing patient quality of life and represents a significant economic burden in oncology. The pathobiology of alimentary mucositis is extremely complex, and an increased understanding of mechanisms and pathway interactions is required to rationally design improved therapies. This review describes the latest advances in defining mechanisms of alimentary mucositis pathobiology in the context of pathway activation. It focuses particularly on the recent genome-wide analyses of regimen-related mucosal injury and the identification of specific regulatory pathways implicated in mucositis development. This review also discusses the currently known alimentary mucositis risk factors and the development of novel treatments. Suggestions for future research directions have been raised.
营养性黏膜炎是一种与癌症治疗相关的主要剂量限制毒性。它会降低患者的生活质量，并在肿瘤学领域造成巨大的经济负担。营养性黏膜炎的病理生物学极其复杂，需要深入了解机制和途径相互作用，才能合理设计出改进的治疗方法。本综述描述了在途径激活的背景下，定义营养性黏膜炎病理生物学机制的最新进展。它特别侧重于最近对方案相关黏膜损伤的全基因组分析，以及确定与黏膜炎发展相关的特定调节途径。本综述还讨论了目前已知的营养性黏膜炎危险因素和新型治疗方法的开发。提出了对未来研究方向的建议。
